Stock Market Reviews

Read and share opinions on VNRX (VolitionRx Limited) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ...
  Nov 14, 2025
• VolitionRX: Q3 Earnings Snapshot
  Nov 13, 2025
• VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
  Nov 13, 2025
• VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
  Nov 10, 2025
• Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
  Oct 17, 2025
• VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
  Oct 10, 2025
• VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
  Oct 9, 2025
• Volition Sponsors Upcoming GenomeWeb Webinar
  Oct 2, 2025
• VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode.
  Oct 1, 2025
• Volition Signs Co-Marketing and Services Agreement with Hologic
  Sep 29, 2025
• Volition Signs First Human Out Licensing Deal
  Sep 9, 2025
• VNRX: Management seeks to secure multiple licensing agreements in the human diagnostic space with the first one expected in 3Q 2025. Key financial goal for 2025 is to be cash neutral on a full year basis.
  Aug 25, 2025
• VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ...
  Aug 16, 2025
• VolitionRX: Q2 Earnings Snapshot
  Aug 14, 2025
• VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
  Aug 14, 2025
• VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
  Aug 8, 2025
• VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
  Aug 4, 2025
• Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
  Jul 16, 2025
• Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
  Jul 8, 2025
• Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
  Jun 12, 2025